75.00 -0.16 (-0.21%)
After hours: 6:53PM EDT
Price Crosses Moving Average
|Bid||75.18 x 800|
|Ask||75.17 x 1100|
|Day's Range||74.38 - 76.90|
|52 Week Range||60.89 - 85.97|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||19.29|
|Earnings Date||Jul 28, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||2.72 (3.49%)|
|Ex-Dividend Date||Jun 11, 2020|
|1y Target Est||80.39|
As protests over the George Floyd case continue to grow, worries over the spread of coronavirus weigh heavily on medical experts as Gilead Sciences and Eli Lilly announce news about their vaccine trials. Yahoo Finance’s Anjalee Khemlani joins The Final Round to break down the latest news about the coronavirus.
Eli Lilly announced the company has started an early-stage trial to test its potential treatment for coronavirus. Yahoo Finance’s Anjalee Khemlani breaks down the latest developments.
Cruise ship stocks rallied on Monday, as optimism for COVID-19 vaccines and treatments rose. A flurry of encouraging coronavirus-related developments in recent days likely contributed to the gains in cruise ship stock prices. On Friday, Moderna (NASDAQ: MRNA) announced the commencement of its phase 2 study for its COVID-19 vaccine, mRNA-1273.
Jim Cramer discusses the stock market today including the protests in America, Gilead Sciences Covid-19 drug disappoints, and Coty's new CEO.
Early Monday, Gilead Sciences reported mixed results for its coronavirus treatment, remdesivir, in patients moderately ill with Covid-19. As a result, GILD stock dipped.
U.S. stocks posted gains on Monday as signs of U.S. economic recovery helped offset jitters over increasingly violent social unrest amid an ongoing pandemic and rising U.S.-China tensions. Market leaders Facebook Inc, Apple Inc and Amazon.com provided the biggest lift to the S&P 500 and the Nasdaq, while Boeing Co gave the Dow its biggest boost. "Certainly the pace of the stock market recovery can't continue at the pace it has been," said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago.
The global coronavirus pandemic converged on Monday with social unrest roiling the U.S., as hopes for relaxing lockdowns were undercut by raucous protests that prompted several big cities to impose curfews.
Protests and trade tensions can’t keep the stock market down as investors continue to focus on the reopening of the U.S. economy from the coronavirus-imposed shutdown.
A slice of data from the third clinical trial for Gilead Sciences Inc.’s remdesivir indicates that the experimental therapy is somewhat effective in treating COVID-19 patients but is not the silver bullet that had been hoped for.
Wall Street stocks posted modest gains on Monday as signs suggesting the U.S. economy may be on the road to recovery helped soothe jitters over increasingly violent social unrest and rising U.S.-China tensions. Market leaders Apple Inc, Amazon.com and Facebook Inc provided the biggest lift to the S&P 500 and the Nasdaq, while Boeing Co provided the blue-chip Dow with its biggest boost.
The number of global cases of the coronavirus that causes COVID-19 climbed above 6 million on Monday, after a weekend dominated by protests across the U.S. at the death of an unarmed black man at the hands of a white police officer in Minneapolis last week.
The first wave of the COVID-19 pandemic may be waning. Scientists in Europe and the United States say the relative success of draconian lockdown and social distancing policies in some areas and countries means virus transmission rates may be at such low levels that there is not enough disease circulating to truly test potential vaccines.
Wall Street's major indexes rose on Monday as investors chose to look past violent protests across the country over racial inequality and focused more on economic data that bolstered views of a quick post-pandemic recovery. U.S. manufacturing activity eased off an 11-year low in May, an Institute for Supply Management (ISM) survey showed, the strongest sign yet that the worst of the economic downturn was behind as businesses reopen.
U.S. stocks struggled for direction on Monday as investors weighed prospects of a post-pandemic economic recovery against protests across the country over race and an ongoing standoff between Washington and Beijing. U.S. manufacturing activity eased off an 11-year low in May, an Institute for Supply Management (ISM) survey showed, the strongest sign yet that the worst of the economic downturn was behind as businesses reopen.
Major stock indexes were higher early Monday on rising U.S.-China tensions. Pfizer dove 7% on a failed drug trial.
Gilead Sciences, Inc. (NASDAQ: GILD) shares have come under selling pressure after the company released results Monday from a Phase 3 study of its COVID-19 treatment candidate remdesivir.Gilead's Mixed Remdesivir Data The company announced topline results from the Phase 3 SIMPLE study in hospitalized patients with moderate COVID-19 pneumonia. The results showed patients in the five-day remdesivir treatment group were 65% more likely to have clinical improvement at day 11 compared with those in the standard of care group.The open-label study evaluated five-day and 10-day courses of remdesivir plus standard of care versus standard of care alone.The 10-day treatment course of remdesivir versus standard of care -- though producing favorable results -- did not reach statistical significance, Gilead said.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.The company noted that no new safety signals were identified in the study."These study results offer additional encouraging data for remdesivir, showing that if we can intervene earlier in the disease process with a five-day treatment course, we can significantly improve clinical outcomes for these patients," said Francisco Marty, a practicing physician and a professor of medicine at Harvard Medical School.Gillead's remdesivir has emergency use authorization in the U.S., while it is approved for COVID-19 treatment in Japan.Gilead said it plans to submit full data for publication in a peer-reviewed journal in the coming months.GILD Price Action Gilead shares were down 4.21% at $74.55 at the time of publication Monday.Related Links:The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight Gilead Works To 'Maximize Global Supply' Of Coronavirus Candidate Remdesivir Amid Threat Of Patent Loss See more from Benzinga * The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer * The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive * The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Gilead said that in its late-stage clinical trials of remdesivir in patients who were moderately ill with Covid-19, those taking the broad-spectrum antiviral medication for five days were 65% more likely to show clinical improvement, compared with those receiving standard care. At the end of April, Gilead released a report showing improvement in patients taking remdesivir in a government-funded trial, although a different study in China did not yield similar results. It’s been a wild ride for Gilead stock, as hopes for remdesivir, created to fight ebola, wax and wane.
Gilead's stock has posted consistent growth this year as a result of its ambitious antiviral drug development program for COVID-19. With the preliminary publication of favorable clinical trial results for Gilead's remdesivir antiviral, the company cemented its earlier growth for the short term. On Thursday, Roche revealed that it was testing Gilead's remdesivir as part of a combination therapy for COVID-19, a move which will doubtlessly be followed by others in the coming weeks.
U.S. stocks edged higher on Monday on prospects of a post-pandemic economic recovery, but the sentiment remained fragile amid protests across the country over race and an ongoing standoff between Washington and Beijing. U.S. manufacturing activity eased off an 11-year low in May, an Institute for Supply Management (ISM) survey showed, the strongest sign yet that the worst of the economic downturn was behind as businesses reopen. The three main indexes had opened lower as National Guard troops were deployed over the weekend in 15 states and Washington, D.C. in an attempt to quell a sixth night of violence that began with peaceful protests over the death of a black man, George Floyd, in police custody.
(Bloomberg) -- Gilead Sciences Inc.’s drug remdesivir showed only a limited benefit in a large trial of more moderate patients with Covid-19, a result that may shift perceptions of the therapy already cleared for use in severe cases of the disease.In the phase 3 trial, a group of moderately ill, hospitalized patients getting the drug for five days showed a modest improvement compared to those getting the standard of care, the company said in a statement. But another group getting the drug for 10 days didn’t show a statistically significant improvement, which is likely to raise questions about why a longer course doesn’t help more. Severely ill patients weren’t included in the trial.The shares fell 2.8% to $75.68 at 9:36 a.m. in New York. They’re up 16% this year, largely on optimism around remdesivir. Gilead’s drug has become a symbol of efforts to reopen the economy and effectively treat patients stricken with the coronavirus. A working therapy would help reduce the risk for people who become sick, providing greater certainty to efforts to reopen economies around the globe.The clinical trial looked at hospitalized Covid-19 patients who had more moderate disease, with pneumonia but who didn’t have reduced oxygen levels at the beginning of the study. Patients were randomly assigned to get five days of remdesivir, 10 days of remdesivir, or the standard of care, and then evaluated on a 7-point scale.Overall, the differences were quite modest. The patents who received five days of remdesivir did best, with 76% improving by at least one point by day 11, compared to 66% who received standard of care.But confusingly, patients who stayed on remdesivir for 10 days did slightly worse than those who received five days of remdesivir, with only 70% of them improving at day 11. That difference wasn’t statistically significant compared to the standard of care group.“There seems to be growing evidence five-day treatment is as good or better than 10-day -- somewhat curious given no clear side-effect liabilities and may seem counter-intuitive to the typical ‘more is better’ expectation,” said Brian Abrahams, an analyst with RBC Capital Markets. He said the difference could be caused by a less burdensome administration of the drug.The U.S. Food and Drug Administration cleared remdesivir under an emergency authorization on May 1, which has allowed hospitalized patients with severe cases of Covid-19 to begin using the therapy. The emergency approval followed early results from a large, placebo-controlled study run by the U.S. government that showed that patients getting remdesivir recovered faster than those that got a placebo.In the new trial, Gilead said there were no new safety risks identified across either treatment group. The company plans to submit the full data for publication in a peer-reviewed medical journal in coming weeks.(Updates with opening share price in the third paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Patients in a five-day treatment group were '65% more likely to have clinical improvement at day 11 compared with those in the standard of care group,' Gilead said.
The stock market comeback persisted last month as the Covid-19 pandemic health situation continued to stabilize and the broader economy accelerated business reopenings Continue reading...